Showing posts with label Neuroendocrine tumors. Show all posts
Showing posts with label Neuroendocrine tumors. Show all posts

Wednesday, 20 December 2023

Role of Immunohistochemical Markers Chromogranin A and Synaptophysin: A Retrospective Analysis for the Outcome of Patients with Pulmonary Carcinoid Tumors | Chapter 22 | Diagnostic and Treatment Advances in COVID-19 and SARS-CoV-2

 Background: Carcinoid tumors are a subset of neuroendocrine tumors, of which pulmonary carcinoid (PC) is the second most common type. PC is divided into typical (TC) and atypical (AC) subtypes. They have a low incidence and a relatively high survival rate. In this study, we report the characteristics, prognosis, and results of PC patients from Gansu Provincial People's Hospital in China to better understand these tumors and their prognostic markers.

Materials and Methods: This is a study based on retrospective chart review in our tertiary referral center. In this study, there were 36 consecutive PC patients enrolled from 2000 to 2017. The information collected including demographics, tumor characteristics, recurrence and survival rates. All patients had their last follow-up visit on December 31, 2020.

Results: 39% of patients were asymptomatic at the time of diagnosis and, most patients suffer from early disease. 80% of patients have typical PC and 20% are atypical PC. Both subtypes have a good prognosis, but the atypical subtype has a higher rate of progression (60%). The median time to disease progression or recurrence is 6 years. Only 2 patients died. Immunohistochemistry (IHC) markers in those tested showed high sensitivity for chromogranin A (82%) and synaptophysin (100%).

Conclusion: Our study provides insights for PC patients with low incidence in Northwest China. Most patients are treated with surgery and have a good survival rate. IHC marking should be better implemented. Larger studies are needed to illustrate and verify our results.


Author(s) Details:

Peihong Li,
Gansu Province People’s Hospital, Lanzhou 730000, China.

Bin Zhu,
Gansu Province People’s Hospital, Lanzhou 730000, China.

Ailing Li,
People’s Hospital of Qilihe District, Lanzhou 730050, China.

Di Chen,
Gansu Medical College, Pingliang 744000, China.

Jianshe Yang,
Gansu Medical College, Pingliang 744000, China.

Please see the link here: https://stm.bookpi.org/DTACSC/article/view/9574

Monday, 26 June 2023

Rare Case of Malignant Insulinoma Treated with Chemoembolization and Bland Embolization | Chapter 13 | Research Highlights in Disease and Health Research Vol. 9

 This division described a unique case of a patient with different presentation of malignant insulinoma. The patient bestowed with right superior quadrant intestinal pain and diarrhea for 3 weeks that have worsened in the last 4- days. Also the patient had scenes of confusion in the last one period. His blood glucose was never inspected at that time.The patient acted not have the classical performance of Insulinoma with the Whipple’s trio- measured abstaining blood glucose less than 50 mg/dl, syndromes of hypoglycemia at the time of depressed plasma level of glucose in blood and immediate free of the symptoms later the administration of intravenous hydrogen. The diarrhea is not a common feature of Insulinoma although commonly happens in additional neuroendocrine tumors like gastrinoma, VIP secreting neuroendocrine tumors, glucagonoma etc.CT of the abdomen that was done because of the patient manifestations revealed 6sm bulk in the tail of the pancreas, accompanying thrombosis of the splenic mood and multiple change of the pancreatic mass to the liver.Our initial though was that the patient has metastatic adenocarcinoma of the organ meat.The endoscopic ultrasound (EUS) of the pancreas was accomplished fine needle hope of the pancreatic mass that showed the demeanor of the neuroendocrine tumor.During whole up of the pancreatic mass we performed 72- moment fasting test that revealed reduced plasma level of glucose in blood less than 55 mg/dl, raised at that time C- peptide, pro-insulin and Insulin levels and negative protect for sulfonylureas medications or glinides. Anti- insulin microscopic organism test was negative as well as Pro- IGF-2. Injection of Glucagon 1 mg intravenously allow to increment               of the level of glucose in blood more than 25 mg/dl in 30 notes of meeting. Beta-hydroxybutyrate level was less than 2.7 nmol/l. All this pointed out towards inner hyperinsulinemia in the context of the performance due to pancreatic insulinoma.This in addition to the EUS and radiological results suggested the occupancy of malignant insulinoma.Thereafter the surgical group was consulted. They acted exploratory laparotomy with distal pancreatectomy, splenectomy, cholecystectomy, and appendectomy and medical checkup of the liver lesions and spleen. Surgical study of plants specimen of the hate and liver was consistent accompanying a well-differentiated neuroendocrine cyst similar to that from the pancreatic lesion.The patient was medicated with surgical redistribute of the distal pancreas when the insulinoma was situated, splenectomy, cholecystectomy and appendectomy. Also, chemoembolization and bland embolization of the metastatic tumors of the liver were finished and patient’s hypoglycemia was treated accompanying Diazoxide and short course of Steroids and Octreotide.We are describing this patient to emphasize the need of broad characteristic diagnosis of the pancreatic lesions giving only with intestinal pain, diarrhea and sporadic confusion outside any measurement of the level of glucose in blood.What looked like chaste metastatic adenocarcinoma of the pancreas equipped to be nonconforming presentation of individual of the Neuroendocrine tumors- Insulinoma. Also only 10% of Insulinomas are malignant that was the case with our patient.We implemented complex complex linked approach in the treatment - surgical redistribute of the pancreatic lesion by distal pancreatectomy in addition to bland and Chemoembolization of the change to the liver. Also, we controlled the level of glucose in blood by using Diazoxide, Prednisone and Octreotide with good results custody the blood sugar in common ranges by long term use of diazoxide.

Author(s) Details:

Nazanin Sheikhan,
Department of Internal Medicine, HCA Healthcare, Mountain View Hospital, Sunrise Health GME Consortium, Las Vegas, Nevada, USA.

Joshua Hardy,
Department of Internal Medicine, HCA Healthcare, Mountain View Hospital, Sunrise Health GME Consortium, Las Vegas, Nevada, USA.

George Trad,
Department of Internal Medicine, HCA Healthcare, Mountain View Hospital, Sunrise Health GME Consortium, Las Vegas, Nevada, USA.

Andrew Nguyen,
Department of Radiology, HCA Healthcare, Mountain View Hospital, Sunrise Health GME Consortium, Las Vegas, Nevada, USA.

Andrey Manov,
Department of Internal Medicine, HCA Healthcare, Mountain View Hospital, Sunrise Health GME Consortium, Las Vegas, Nevada, USA.

Please see the link here: https://stm.bookpi.org/RHDHR-V9/article/view/10980